NGM BIOPHARMACEUTICALS INC (NGM) Stock Price, Quote, News and Overview
NASDAQ:NGM - Nasdaq - US62921N1054 - Common Stock - Currency: USD
NGM Quote, Performance and Key Statistics
1.54
-0.02 (-1.28%)
The current stock price of NGM is 1.54 USD. In the past month the price increased by 1.32%. In the past year, price decreased by -59.79%.
NGM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About NGM
Company Profile
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company is headquartered in South San Francisco, California and currently employs 239 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying grievous diseases with critical unmet or underserved patient need. The Company’s portfolio of product candidates includes NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin, NGM936 and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). The firm's NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.
Company Info
NGM BIOPHARMACEUTICALS INC
333 Oyster Point Blvd
South San Francisco CALIFORNIA 94080 US
CEO: David J. Woodhouse
Employees: 239
Company Website: https://www.ngmbio.com/
Phone: 16502435555
NGM BIOPHARMACEUTICALS INC / NGM FAQ
What is the stock price of NGM BIOPHARMACEUTICALS INC today?
The current stock price of NGM is 1.54 USD. The price decreased by -1.28% in the last trading session.
What is the ticker symbol for NGM BIOPHARMACEUTICALS INC stock?
The exchange symbol of NGM BIOPHARMACEUTICALS INC is NGM and it is listed on the Nasdaq exchange.
On which exchange is NGM stock listed?
NGM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NGM BIOPHARMACEUTICALS INC stock?
11 analysts have analysed NGM and the average price target is 1.7 USD. This implies a price increase of 10.11% is expected in the next year compared to the current price of 1.54. Check the NGM BIOPHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NGM BIOPHARMACEUTICALS INC worth?
NGM BIOPHARMACEUTICALS INC (NGM) has a market capitalization of 128.53M USD. This makes NGM a Micro Cap stock.
How many employees does NGM BIOPHARMACEUTICALS INC have?
NGM BIOPHARMACEUTICALS INC (NGM) currently has 239 employees.
What are the support and resistance levels for NGM BIOPHARMACEUTICALS INC (NGM) stock?
NGM BIOPHARMACEUTICALS INC (NGM) has a support level at 1.53 and a resistance level at 1.54. Check the full technical report for a detailed analysis of NGM support and resistance levels.
Is NGM BIOPHARMACEUTICALS INC (NGM) expected to grow?
The Revenue of NGM BIOPHARMACEUTICALS INC (NGM) is expected to decline by -100% in the next year. Check the estimates tab for more information on the NGM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NGM BIOPHARMACEUTICALS INC (NGM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NGM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NGM, evaluating the profitability, health, valuation and growth aspects
- NGM BIOPHARMACEUTICALS INC (NGM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NGM BIOPHARMACEUTICALS INC (NGM) Sales and EPS estimates to see what analysts future expectations are.
- NGM BIOPHARMACEUTICALS INC (NGM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NGM BIOPHARMACEUTICALS INC (NGM) Insider and Institutional Ownership to learn about the owners and their transactions.
- NGM BIOPHARMACEUTICALS INC (NGM) Stock Chart to make your own analysis
- NGM BIOPHARMACEUTICALS INC (NGM) Latest news and press-releases to stay up to date.
Does NGM BIOPHARMACEUTICALS INC (NGM) stock pay dividends?
NGM does not pay a dividend.
When does NGM BIOPHARMACEUTICALS INC (NGM) report earnings?
NGM BIOPHARMACEUTICALS INC (NGM) will report earnings on 2024-05-02, after the market close.
What is the Price/Earnings (PE) ratio of NGM BIOPHARMACEUTICALS INC (NGM)?
NGM BIOPHARMACEUTICALS INC (NGM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
NGM Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NGM. When comparing the yearly performance of all stocks, NGM is a bad performer in the overall market: 85.63% of all stocks are doing better.
NGM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NGM. While NGM has a great health rating, there are worries on its profitability.
NGM Financial Highlights
Over the last trailing twelve months NGM reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS increased by 16.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.31% | ||
| ROE | -95.79% | ||
| Debt/Equity | 0 |
NGM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to NGM. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 29.44% and a revenue growth -100% for NGM